Should Canadian Benefits Plans Cover Ozempic and Wegovy for Diabetes and Weight Management?

Demand for GLP-1 drugs has forced a hard question onto Canadian benefits plan renewal tables: should coverage follow the diagnosis, the drug, the expected health outcome, or the budget impact?

Ozempic and Wegovy are both semaglutide products, but they are not interchangeable from a benefits policy point of view. Ozempic is commonly associated with type 2 diabetes treatment. Wegovy is associated with chronic weight management. That distinction matters because Canadian insurers, employers and advisors often assess diabetes drugs differently from anti-obesity medications.

The right answer is rarely a simple yes or no. A better question is: what coverage policy can support health needs while keeping the plan financially sustainable?

GLP-1 coverage decisions often start at the pharmacy counter.

Why GLP-1 coverage is now a plan design issue

GLP-1 drugs can carry a high recurring cost compared with many traditional maintenance medications. For a benefits plan, that creates two pressures at once.

First, there is clinical demand. Employees and dependants may seek coverage for diabetes management, weight management, or both. Some may already have prescriptions and expect their plan to respond.

Second, there is plan risk. If coverage is broad and unmanaged, utilization can rise quickly. If coverage is too narrow, the plan may fail to support people with legitimate medical needs.

That tension now sits inside broader conversations about employee benefits Canada, including drug plan sustainability, chronic disease support and equity across employee groups.

Diabetes coverage and weight-management coverage should not be treated the same

A clear policy starts by separating the two main use cases.

Coverage question	Type 2 diabetes	Weight management
Main plan rationale	Treating a recognized chronic disease	Treating obesity or overweight with related risk factors
Common review method	Prior authorization or step therapy	Prior authorization with stricter eligibility rules
Key documentation	Diagnosis, lab history, previous therapies	BMI criteria, related health conditions, treatment plan
Plan risk	High but easier to define clinically	Potentially broader eligible population

For diabetes, GLP-1 coverage often fits within an established drug plan framework. Many Canadian plans already cover diabetes medications, with controls for higher-cost therapies. Insurers may ask whether the person has type 2 diabetes, whether other first-line therapies have been tried, and whether the prescription follows accepted clinical practice.

Weight-management coverage is more complex. Obesity is a chronic medical condition, but many legacy benefits plans exclude weight-loss drugs or treat them as lifestyle products. That approach is increasingly out of step with current medical thinking, yet the cost exposure can be significant if a plan opens coverage without clear criteria.

A thoughtful plan can acknowledge obesity as a health condition while still setting limits.

Diabetes and weight management needs can overlap, but plan rules should stay clear.

Eligibility controls make coverage more defensible

Eligibility controls are not just cost barriers. Used well, they help align coverage with medical need and reduce inconsistent decisions.

Common Canadian plan controls include:

• Prior authorization

The claimant or prescriber submits clinical information before the drug is approved.

• Diagnosis-based criteria

The plan distinguishes type 2 diabetes from weight-management use.

• Step therapy

The claimant may need to try lower-cost or standard therapies first, when clinically appropriate.

• BMI and comorbidity criteria

For weight management, plans may require a BMI threshold and related health risks, such as hypertension, sleep apnea or dyslipidemia.

• Renewal criteria

Coverage may continue only if the member meets agreed clinical markers or the prescriber confirms ongoing benefit.

• Quantity and dosing limits

The plan aligns reimbursement with approved dosing schedules.

These controls should be easy to explain. If employees cannot understand why one claim is approved and another is declined, the policy will feel arbitrary.

The plan document, booklet and insurer adjudication rules should match. Misalignment creates appeal risk, employee frustration and administrative back-and-forth.

Cost considerations need more than a drug price discussion

The sticker price matters, but it is only one part of the decision. Plan sponsors should look at total exposure.

Key cost questions include:

1. How many members could qualify?

   Diabetes eligibility is usually narrower than weight-management eligibility. Weight-management criteria can expand the potential claimant pool.

   
   

2. Will the plan cover one indication, both, or neither?

   Covering Ozempic for diabetes does not automatically mean covering Wegovy for weight management. The policy should say so clearly.

   
   

3. How will renewals be handled?

   GLP-1 therapy may be long term. A one-time approval process may not be enough.

   
   

4. What funding model applies?

   Fully insured, refund accounting and administrative services only arrangements can feel the impact differently. Stop-loss or pooling arrangements may not remove all cost pressure.

   
   

5. What happens to employee expectations?

   Once a plan covers weight-management medication, removing that coverage later can be difficult from a culture and communication standpoint.

   
   

Cost management should also include pharmacy plan basics. Mandatory generic substitution will not solve GLP-1 costs where no lower-cost equivalent exists, but reasonable dispensing fee controls, preferred pharmacy arrangements and drug utilization review can still help.

Three coverage approaches Canadian employers are using

Most plan sponsors land somewhere among three options.

Cover GLP-1 drugs for diabetes only

This is the most conservative approach. It protects established diabetes coverage while excluding weight-management indications.

It may be easier to budget and administer, but it can frustrate employees who view obesity treatment as legitimate health care.

Cover diabetes and limited weight-management use

This middle path is becoming more relevant. The plan covers diabetes treatment under established rules and allows weight-management coverage only when strict clinical criteria are met.

This approach works best when the insurer can administer prior authorization clearly and consistently.

Use a flexible benefits design

Some employers may place weight-management drugs in a health spending account or wellness-related allocation rather than the core drug plan. This can support choice while capping employer exposure.

This approach should be reviewed carefully. Tax treatment, plan wording and insurer administration matter. It may not provide enough support for employees with high medical need, but it can be useful in group benefits plans that already include flexible employee benefits and respond to workplace benefits trends.

Communication will make or break the policy

A GLP-1 decision touches health, privacy, stigma and fairness. Communication should avoid moral judgment and focus on plan rules.

A strong message explains:

• what the plan covers

• which indications are eligible

• what documentation is required

• how prior authorization works

• how appeals are handled

• where employees can ask confidential questions

  
  

Managers should not handle medical details. Employees should be directed to the insurer, benefits administrator or confidential support channels.

This content is for general information only and is not medical, legal, tax or benefits advice. Plan sponsors should work with their benefits advisor, insurer and legal counsel before changing coverage.

The best answer is a controlled yes, not an automatic no

Canadian benefits plans do not need to choose between open-ended GLP-1 coverage and blanket exclusion. The stronger approach is to define the medical purpose, set fair eligibility controls and review cost exposure before claims accelerate.

For many plans, that means covering GLP-1 drugs for type 2 diabetes under existing drug rules, then making a separate, deliberate decision on weight-management coverage.

The plans that handle this well will be clear, consistent and prepared. They will support legitimate health needs without leaving the benefits budget to chance.